ERBB2 and inflammatory breast carcinoma: The exact mechanism behind this hyperactivation remains unclear, but some studies suggest that HER2 and active RIPK2 in IBC are positively correlated due to the downregulation of Erbin, removing its inhibitory effect on NOD2/RIPK2 signaling.